Clinical Trials Evaluating Angiotensin-Converting Enzyme Inhibitors Compared with Diuretic or β-Blocker.
| Study Endpoints | CAPPP9 RR (95% CI)* | STOP-210 RR (95% CI)* |
|---|---|---|
| Combined primary endpoint | ||
| Fatal and nonfatal myocardial infarction and stroke, or other cardiovascular deaths | 1.05 (0.90–1.22) | |
| Fatal myocardial infarction, fatal stroke, or other fatal cardiovascular disease | 1.01 (0.84–1.22) | |
| Other endpoints | ||
| Fatal and nonfatal myocardial infarction | 0.96 (0.77–1.19) | 0.90 (0.72–1.13) |
| Fatal and nonfatal stroke | 1.25†(1.01–1.55) | 0.90 (0.74–1.08) |
| All major cardiovascular events | 0.94 (0.83–1.06) | 0.94 (0.82–1.07) |
| Cardiovascular mortality | 0.77 (0.57–1.04) | 1.01 (0.84–1.22) |
| Total morbidity | 0.93 (0.76–1.14) | 1.02 (0.89–1.18) |
RR = relative risk, CI = confidence interval.
* Angiotensin-converting enzyme inhibitor compared with diuretic or β-blocker.
† P = .044.